JP2013503192A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013503192A5 JP2013503192A5 JP2012527033A JP2012527033A JP2013503192A5 JP 2013503192 A5 JP2013503192 A5 JP 2013503192A5 JP 2012527033 A JP2012527033 A JP 2012527033A JP 2012527033 A JP2012527033 A JP 2012527033A JP 2013503192 A5 JP2013503192 A5 JP 2013503192A5
- Authority
- JP
- Japan
- Prior art keywords
- residues
- antigen
- binding fragment
- monoclonal antibody
- mip
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 54
- 102000036639 antigens Human genes 0.000 claims 54
- 108091007433 antigens Proteins 0.000 claims 54
- 239000012634 fragment Substances 0.000 claims 54
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 32
- 102000001902 CC Chemokines Human genes 0.000 claims 23
- 108010040471 CC Chemokines Proteins 0.000 claims 23
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 17
- 108700012434 CCL3 Proteins 0.000 claims 16
- 102000000013 Chemokine CCL3 Human genes 0.000 claims 16
- 102000001326 Chemokine CCL4 Human genes 0.000 claims 16
- 108010055165 Chemokine CCL4 Proteins 0.000 claims 16
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 16
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims 16
- 230000000890 antigenic effect Effects 0.000 claims 15
- 210000004408 hybridoma Anatomy 0.000 claims 13
- 102100036850 C-C motif chemokine 23 Human genes 0.000 claims 10
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 claims 10
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 9
- 102100023705 C-C motif chemokine 14 Human genes 0.000 claims 8
- 102100023703 C-C motif chemokine 15 Human genes 0.000 claims 8
- 102100023701 C-C motif chemokine 18 Human genes 0.000 claims 8
- 101000978381 Homo sapiens C-C motif chemokine 14 Proteins 0.000 claims 8
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 claims 8
- 101000978371 Homo sapiens C-C motif chemokine 18 Proteins 0.000 claims 8
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 101000728693 Homo sapiens 28S ribosomal protein S11, mitochondrial Proteins 0.000 claims 4
- 101000856395 Homo sapiens Cullin-9 Proteins 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 claims 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 230000035605 chemotaxis Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23801509P | 2009-08-28 | 2009-08-28 | |
| US61/238,015 | 2009-08-28 | ||
| PCT/US2010/047004 WO2011025962A1 (en) | 2009-08-28 | 2010-08-27 | Antikine antibodies that bind to multiple cc chemokines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016011829A Division JP2016135783A (ja) | 2009-08-28 | 2016-01-25 | 複数種のＣＣケモカインと結合するａｎｔｉｋｉｎｅ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013503192A JP2013503192A (ja) | 2013-01-31 |
| JP2013503192A5 true JP2013503192A5 (enExample) | 2013-09-19 |
| JP6109571B2 JP6109571B2 (ja) | 2017-04-05 |
Family
ID=43628404
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012527033A Active JP6109571B2 (ja) | 2009-08-28 | 2010-08-27 | 複数種のＣＣケモカインと結合するａｎｔｉｋｉｎｅ抗体 |
| JP2016011829A Pending JP2016135783A (ja) | 2009-08-28 | 2016-01-25 | 複数種のＣＣケモカインと結合するａｎｔｉｋｉｎｅ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016011829A Pending JP2016135783A (ja) | 2009-08-28 | 2016-01-25 | 複数種のＣＣケモカインと結合するａｎｔｉｋｉｎｅ抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8313747B2 (enExample) |
| EP (1) | EP2470671B1 (enExample) |
| JP (2) | JP6109571B2 (enExample) |
| KR (1) | KR101778813B1 (enExample) |
| CN (1) | CN102782148B (enExample) |
| AU (1) | AU2010286516B2 (enExample) |
| BR (1) | BR112012004387A2 (enExample) |
| CA (1) | CA2771781C (enExample) |
| DK (1) | DK2470671T3 (enExample) |
| ES (1) | ES2531561T3 (enExample) |
| HR (1) | HRP20150162T1 (enExample) |
| IN (1) | IN2012DN01769A (enExample) |
| MX (1) | MX2012002427A (enExample) |
| PL (1) | PL2470671T3 (enExample) |
| PT (1) | PT2470671E (enExample) |
| SI (1) | SI2470671T1 (enExample) |
| SM (1) | SMT201500011B (enExample) |
| WO (1) | WO2011025962A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2470671T1 (sl) * | 2009-08-28 | 2015-04-30 | Regeneron Pharmaceuticals, Inc. | Antikinska protitelesa, ki se veĺ˝ejo na veäś kemokinov cc |
| DK2717941T3 (da) * | 2011-06-13 | 2020-07-13 | Tla Targeted Immunotherapies Ab | Behandling af cancer |
| WO2013033206A2 (en) * | 2011-08-29 | 2013-03-07 | University Of Rochester | Compositions and methods for inhibiting ccl3 |
| WO2013036290A1 (en) * | 2011-09-09 | 2013-03-14 | Yale University | Compositions and methods for assessing and treating inflammatory diseases and disorders |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| JO3580B1 (ar) * | 2013-03-15 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لكيموكين elr+ cxc شامل |
| AU2014268316B2 (en) | 2013-05-23 | 2019-10-10 | Takeda Pharmaceutical Company Limited | Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma |
| JP6220222B2 (ja) * | 2013-10-28 | 2017-10-25 | シスメックス株式会社 | 関節リウマチの診断を補助するための方法、システム及びコンピュータプログラム製品 |
| SMT201900714T1 (it) * | 2013-12-09 | 2020-01-14 | Allakos Inc | Anticorpi anti-siglec-8 e loro metodi d'impiego |
| EP4014995A1 (en) | 2014-02-28 | 2022-06-22 | Allakos Inc. | Methods and compositions for treating siglec-8 associated diseases |
| RU2705255C2 (ru) * | 2014-03-04 | 2019-11-06 | Хемомаб Лтд. | Антитела против эотаксина 2, которые распознают дополнительные связывающие CCR3 хемокины |
| CN104198727A (zh) * | 2014-08-22 | 2014-12-10 | 广西南宁隆吉维特生物科技有限公司 | 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法 |
| TWI566780B (zh) * | 2014-10-24 | 2017-01-21 | 國立陽明大學 | 巨噬細胞發炎蛋白－１β（ＭＩＰ－１β）抑制劑用於促進血管新生以改善組織缺血及糖尿病血管病變的用途 |
| EP4399969A3 (en) | 2014-12-09 | 2024-10-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 274 gene |
| US10774145B2 (en) | 2015-06-17 | 2020-09-15 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
| US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
| CA3029003A1 (en) | 2016-06-27 | 2018-01-04 | The Regents Of The University Of California | Cancer treatment combinations |
| EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| WO2018159787A1 (ja) * | 2017-03-01 | 2018-09-07 | 国立大学法人北海道大学 | 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法 |
| MX2019011958A (es) * | 2017-04-05 | 2019-12-11 | Korea Res Inst Bioscience & Biotechnology | Proteína de fusión activadora de células nk, célula nk, y composición farmacéutica que las incluye. |
| EA201992626A1 (ru) | 2017-05-05 | 2020-04-24 | Аллакос Инк. | Способы и композиции для лечения аллергических заболеваний глаз |
| WO2019037067A1 (zh) * | 2017-08-25 | 2019-02-28 | 法玛科技顾问股份有限公司 | 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以治疗及控管动脉粥状硬化的用途 |
| WO2019075472A1 (en) * | 2017-10-13 | 2019-04-18 | A&G Pharmaceutical, Inc. | MONOCLONAL AND CONJUGATED ANTIBODIES AGAINST THE PROSTAGLANDIN F2 RECEPTOR INHIBITOR AND USES THEREOF |
| EP3732196A4 (en) | 2017-12-28 | 2022-01-05 | Astute Medical, Inc. | ANTIBODIES AND ASSAYS FOR CCL14 |
| US12352758B2 (en) | 2018-02-26 | 2025-07-08 | Cornell University | Quantitative biomarkers of EHV-1 susceptibility and protection |
| CA3099974A1 (en) * | 2018-05-11 | 2019-11-14 | Halcyon Therapeutics, Inc. | Binding proteins and chimeric antigen receptor t cells targeting gasp-1 granules and uses thereof |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN110117329B (zh) * | 2019-04-03 | 2020-12-08 | 河北浓孚雨生物科技有限公司 | 包含趋化因子与结合伴侣的融合多肽及其用途 |
| AU2020300544B2 (en) * | 2019-07-02 | 2024-07-25 | Astute Medical, Inc | Antibodies and assays for CCL14 |
| KR102489282B1 (ko) * | 2019-07-02 | 2023-01-17 | 고려대학교 산학협력단 | Ccl4, ccl5, ccl20, 및 ccl21을 유효성분으로 포함하는 임신촉진용 조성물 |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CN113893331B (zh) * | 2020-07-06 | 2024-11-26 | 中国农业科学院特产研究所 | 一种诱导母鹿生茸的产品及其制备方法和诱导母鹿生茸的方法和应用 |
| WO2022011110A2 (en) * | 2020-07-08 | 2022-01-13 | Georgia Tech Research Corporation | Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection |
| MX2023004349A (es) | 2020-10-16 | 2023-08-22 | Lanova Medicines Ltd | Anticuerpos monoclonales anti-ccr8 y sus usos. |
| CN115598111B (zh) * | 2021-07-08 | 2025-03-25 | 南京大学 | 基于邻位诱导免疫分析的特异性杂交瘤细胞化学发光筛选方法 |
| CN114990073A (zh) * | 2022-05-27 | 2022-09-02 | 河南农业大学 | 一种抗猪ccl2蛋白的单克隆抗体及其制备方法和应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US6498015B1 (en) * | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
| US7018627B1 (en) | 1995-06-07 | 2006-03-28 | Icos Corporation | Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof |
| US6316420B1 (en) * | 1998-07-28 | 2001-11-13 | Technion Research And Development Foundation Ltd. | DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis |
| US6420346B1 (en) * | 2000-02-07 | 2002-07-16 | Rappaport Family Institute For Research In The Medical Sciences | Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis |
| EP1542724A4 (en) | 2002-08-19 | 2005-10-19 | Abgenix Inc | ANTIBODIES AGAINST THE MONOCYTE 1 CHIMIOATTRACTIVE PROTEIN (MCP-1) AND USES THEREOF |
| CA2507080C (en) | 2002-11-27 | 2015-01-06 | Biogen Idec Ma Inc. | Humanized antibodies against monocyte chemotactic proteins |
| WO2006067124A2 (en) * | 2004-12-21 | 2006-06-29 | Laboratoires Serono S.A. | Cc-chemokine antagonists |
| EP2185719B1 (en) * | 2007-08-02 | 2013-11-13 | NovImmune SA | Anti-rantes antibodies and methods of use thereof |
| SI2470671T1 (sl) * | 2009-08-28 | 2015-04-30 | Regeneron Pharmaceuticals, Inc. | Antikinska protitelesa, ki se veĺ˝ejo na veäś kemokinov cc |
-
2010
- 2010-08-27 SI SI201030901T patent/SI2470671T1/sl unknown
- 2010-08-27 BR BR112012004387A patent/BR112012004387A2/pt active Search and Examination
- 2010-08-27 JP JP2012527033A patent/JP6109571B2/ja active Active
- 2010-08-27 PL PL10812667T patent/PL2470671T3/pl unknown
- 2010-08-27 KR KR1020127007885A patent/KR101778813B1/ko not_active Expired - Fee Related
- 2010-08-27 CA CA2771781A patent/CA2771781C/en active Active
- 2010-08-27 AU AU2010286516A patent/AU2010286516B2/en active Active
- 2010-08-27 WO PCT/US2010/047004 patent/WO2011025962A1/en not_active Ceased
- 2010-08-27 ES ES10812667.3T patent/ES2531561T3/es active Active
- 2010-08-27 DK DK10812667T patent/DK2470671T3/en active
- 2010-08-27 MX MX2012002427A patent/MX2012002427A/es active IP Right Grant
- 2010-08-27 EP EP20100812667 patent/EP2470671B1/en active Active
- 2010-08-27 PT PT10812667T patent/PT2470671E/pt unknown
- 2010-08-27 US US12/870,573 patent/US8313747B2/en active Active
- 2010-08-27 CN CN201080048961.XA patent/CN102782148B/zh not_active Expired - Fee Related
- 2010-08-27 IN IN1769DEN2012 patent/IN2012DN01769A/en unknown
- 2010-08-27 HR HRP20150162TT patent/HRP20150162T1/hr unknown
-
2012
- 2012-10-22 US US13/657,120 patent/US9005617B2/en active Active
-
2015
- 2015-01-16 SM SM201500011T patent/SMT201500011B/xx unknown
- 2015-02-24 US US14/630,112 patent/US20150166647A1/en not_active Abandoned
-
2016
- 2016-01-25 JP JP2016011829A patent/JP2016135783A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013503192A5 (enExample) | ||
| HRP20150162T1 (hr) | Antikin antitijela koja se vežu na višestruke cc kemokine | |
| RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| EP2890711B1 (en) | Method for producing antibody molecules having inter-species, intra-target cross-reactivity | |
| JP2010526028A5 (enExample) | ||
| NZ601586A (en) | Antagonist anti-il-7 receptor antibodies and methods | |
| RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
| JP2013538057A5 (enExample) | ||
| JP2013545438A5 (enExample) | ||
| RU2015111563A (ru) | Способы лечения патологических состояний антителами, которые связываются с рецептором колониестимулирующего фактора 1 (csf1r) | |
| JP2012531922A5 (ja) | Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位 | |
| JP2014526898A5 (enExample) | ||
| JP2007262074A5 (enExample) | ||
| JP2013198490A5 (enExample) | ||
| JP2011520898A5 (enExample) | ||
| RU2010132647A (ru) | Анти-mif антитела | |
| JP2014500009A5 (enExample) | ||
| JP2012143232A5 (enExample) | ||
| NZ712762A (en) | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r | |
| HRP20191342T1 (hr) | Anti-phf-tau antitijela i njihove upotrebe | |
| JP2010527939A5 (enExample) | ||
| JP2016505556A5 (enExample) | ||
| JP2015028021A5 (enExample) | ||
| JP2017508461A5 (enExample) | ||
| JP2014524733A5 (enExample) |